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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease with death on average
within 2–3 years of symptom onset. Mutations in superoxide dismutase 1 (SOD1) have been identified to cause
ALS. Riluzole, the only neuroprotective drug for ALS provides life extension of only 3 months on average.
Thishighlights the need for compound screening in disease models to identify new neuroprotective therapies for
this disease. Zebrafish is an emerging model system that is well suited for the study of diseasepathophysiology and
also for high throughput (HT) drug screening. The mutant sod1 zebrafish model of ALS mimics the hallmark
features of ALS. Using a fluorescence based readout of neuronal stress, we developed a high throughput (HT)
screen to identify neuroprotective compounds.
Results: Here we show that the zebrafish screen is a robust system that can be used to rapidly screen thousands
ofcompounds and also demonstrate that riluzole is capable of reducing neuronal stress in this model system. The
screen shows optimal quality control, maintaining a high sensitivity and specificity withoutcompromising
throughput. Most importantly, we demonstrate that many compounds previously failed in human clinical trials,
showed no stress reducing activity in the zebrafish assay.
Conclusion: We conclude that HT drug screening using a mutant sod1 zebrafish is a reliable model system which
supplemented with secondary assays would be useful in identifying drugs with potential for neuroprotective
efficacy in ALS.
Background
Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disorder that leads to death on average
within 2–3 years of symptom onset. It is characterised by
the progressive loss of upper and lower motor neurons in
the motor cortex, brainstem and spinal cord leading to
muscle wasting, weakness and eventual paralysis. ALS is
predominantly a sporadic disease, but 5–10 % of cases are
familial, usually with autosomal dominant inheritance.
Over 150 mutations in superoxide dismutase 1 (SOD1)
have been identified to cause ALS and several of these
mutations have been modelled in multiple species, includ-
ing mice and zebrafish [1–5]. The only drug currently ap-
proved for slowing disease progression in ALS is riluzole,
which gives ALS patients a life extension of only 3 months
on average [6]. This highlights the need for compound
screening in disease models to identify new neuroprotec-
tive therapies for this devastating human disease.
High throughput screening (HTS) assays underpin
drug discovery efforts as they enable rapid screening of a
large library of bioactive molecules in multiple disease
models. High throughput screens are typically classified
as either target directed drug discovery screens (TDDS)
or as phenotypic drug discovery screens (PDDS) [7, 8].
In target based screens manipulation of a known
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molecular target is the primary goal, with a main focus
on the use of technology for generating throughput. In
contrast, phenotypic screens use a top—down approach,
where a disease process is manipulated in a screen and
the assay uncovers compounds that directly impact on
the disease process. Phenotypic screens typically have a
lower throughput due to the complexity of the pathways
and models used [7, 8]. With advances in genomics and
the identification of molecular targets for many diseases,
target-based approaches have been the main drivers of
drug discovery in the 20th and 21st centuries. However, a
recent report indicates that phenotypic screens are still
the main providers of new-in-class drugs emerging into
the clinic [9]. Among the 45 first-in-class drugs ap-
proved by the FDA during the period of 1999 to 2008,
28 drugs were discovered using PDDS, while only 17
were discovered by applying the TDDS method [9]. This
occurred despite the fact that the majority of drug dis-
covery efforts during this period were primarily geared
towards TDDS based approaches [9].
Neurodegeneration is a field where target based ap-
proaches are yet to convincingly demonstrate utility in
drug discovery. Furthermore, drug failure rates from
bench to clinic in the CNS arena are far higher than in
any other disease areas [10]. The lack of understanding in
the molecular mechanisms that underlie neurodegenera-
tion, and the lack of clear and specific targets, have played
an important role in the poor success rates of drug discov-
ery in neurodegeneration [11]. This highlights a need for
new models and carefully designed screens/trials within
the neurodegenerative field. The advantages of using
PDDS in neurodegeneration are particularly compelling,
as the assays developed will be generally unbiased towards
a specific target, and may be able to modulate a functional
phenotype associated with disease aetiology, multiple mo-
lecular pathways and/or symptoms in human patients.
Zebrafish (Danio rerio) are now widely used as in vivo
models for many human neurological diseases, including
ALS [2, 3, 5, 12–14]. Zebrafish are very useful for model-
ling human disease and drug screening due to their rapid
development, large numbers of offspring, external fertilisa-
tion, small size, susceptibility to genetic manipulation and
transparency during development, making them an excel-
lent model system for imaging [3, 5]. Zebrafish are an in-
creasingly powerful model in the field of high-throughput
in vivo compound screening and have been used to assess
both drug efficacy and toxicity [15, 16]. The development
of a zebrafish Sod1 G93R model of ALS showed that zeb-
rafish mimic many aspects of the human disease [5]. The
mutant Sod1 zebrafish showed hallmark features of ALS
that included impaired swimming ability, reduced muscle
strength, neuromuscular denervation and loss of motor
neurons [5]. Additionally, we have recently shown that
inhibitory interneurons are primarily affected at the
embryonic stage in this zebrafish model, long before the
motor neurons exhibit pathological changes [3]. This sug-
gests that protection of the inhibitory interneurons at this
early embryonic stage may delay the motor neuron degen-
eration observed in adult zebrafish. These findings are in
keeping with recent evidence from human patients indi-
cating that ALS is a disease with a prolonged prodromal
stage which may warrant early intervention [17–22].
Heat shock proteins (HSP’s) are ubiquitously expressed
and found in all organisms. These proteins are up-
regulated in response to increased temperature as well
as other forms of stress, including cellular stress [23, 24].
Heat shock proteins were first identified in 1962 in a
Drosophila model where an increase in temperature was
seen to induce new RNA synthesis [25]. The main func-
tion of the heat shock response is as a protective mech-
anism involved in the unfolded protein response (UPR),
to overcome and promote cell survival in the face of a
toxic insult, such as the presence of mutant or misfolded
protein species, as is the case in SOD1 mutations. The
heat shock response induces the synthesis of a family of
heat shock proteins, including hsp70, that act as chaper-
ones, which attempt to refold misfolded proteins or tar-
get them for degradation. Therefore heat shock proteins
represent an excellent marker of cellular stress and can
be used as a readout for mutation driven toxicity. In fact
western blotting analysis in the sod1 G93A mouse model
of ALS, demonstrated up-regulation of Hsp70 in the
brain and spinal cord at 8 months of age [26].
Using an Hsp70-DsRed reporter gene we have devel-
oped a neuronal stress readout in a mutant Sod1 zebra-
fish model of ALS [5]. As the inhibitory interneurons are
affected at the early embryonic/larval stages and exhibit
activation of a heatshock stress response, we deduced
that a readout of hsp70 activation by quantitation of the
DsRed fluorescence signal could generate a simple high
throughput screen suitable for the identification of mod-
ulators of neuronal stress in the zebrafish model. Inter-
estingly, we found that riluzole, the only neuroprotective
therapy authorised for the treatment of ALS, was able to
reduce the neuronal stress signalled by hsp70 activation.
We sought to develop an in vivo high throughput screen
based on the identification of compounds which could
modulate the quantifiable fluorescent readout of neur-
onal stress. Our screen utilises a high-capacity liquid
handling system and a high-content imaging system to
deliver high-throughput drug screening in an in vivo
model. By screening for compounds that activate or
inhibit the hsp70-DsRed response, we can identify com-
pounds that act upstream or downstream of the mutant
Sod1 toxicity pathway (Fig. 1). Thus, this hybrid assay
combines a target based approach that can differentiate
upstream and downstream pathways and at the same
time has the advantages of a phenotypic screen, as it
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involves measuring the pharmacological modulation of a
pathophysiological readout. In this study we describe the
identification, optimisation, quality control and statistical
analysis of the zebrafish neuronal stress (ZNStress) assay
using a mutant Sod1 G93R zebrafish model of ALS. The
Spectrum library of 2000 compounds was screened in
the ZNStress assay, to identify modulators of neuronal
stress using an hsp70-DsRed readout as a marker of
neuronal stress. We demonstrate here the reproducibil-
ity and throughput of the assay and the ability of a
phenotypic in vivo screen to match the statistical robust-
ness of a TDDS.
Methods
Animals
Adult and larvae zebrafish (Danio Rerio) were kept at
the University of Sheffield Zebrafish Facility, main-
tained at 28.5 °C and bred according to established pro-
cedures [27]. Animal protocols were undertaken in line
with a Home Office approved project licence. The care
and maintenance of animals were performed under the
Home Office project licence as per ASPA regulations.
All experiments were performed with embryos gener-
ated by out crossing the G93Ros10-SH1 line with the
wildtype AB zebrafish strain [3].
Compound library and storage conditions
The spectrum library (Microsource Inc) is a collection of
2000 compounds from the US drug collection, inter-
national drug collection and natural plant compounds.
The Library is stored in deep well storage plates within
the SPOD system (Roylan) to prevent library deterior-
ation. The SPOD system is a specialised drug storage
system designed to extend the lifespan of compound li-
braries by controlling environmental conditions (atmos-
pheric pressure of 0.5PSI, oxygen level <10 %, relative
humidity <5 %) and maintaining an inert environment
by mixing with N2. To create a screening library, the
stock library was imprinted onto 384 well LDV plates
(Labcyte) before dilution to 10 mM to generate a final
well volume of 10 μM. All drugs used in the ZNstress
assay and spectrum library were solubilized and deliv-
ered in DMSO.
ZNStress assay protocol
Embryos were manually dechorinated at 24 h before load-
ing into 96 well plates (Grenier BioOne, μClear) in 70 μl
of E3 media and imaged using the Incell Analyser 2000,
high-content imaging system (GE healthcare) to genotype
the zebrafish prior to initiating the screen for DsRed fluor-
escence. Only normally developed healthy appearing em-
bryos with expected fluorescence patterns are selected for
screening (Additional file 1: Figure S1). All drugs were sol-
ubilized in DMSO with a final maximal DMSO concentra-
tion of 0.1 % and hence 0.1 % DMSO is used as a negative
control. The drugs were loaded onto screening plates
using the Echo 550 liquid handling system (Labcyte) to ac-
curately and rapidly transfer the spectrum library of com-
pounds into assay plates at a final drug concentration of
10 μM in 200 μl. The zebrafish transfered into the drug
solution at 48hpf and incubated at 28 °C until 6dpf. The
plates are monitored each day for death and imaged
again at 6 dpf using Incell Analyzer. Wells with dead
and defective embryos are noted and excluded. The
zebrafish larvae are then terminally anaesthetised using
MS-222 (Sigma), transferred individually in 50 μl to V-
bottom 96 well plates (Grenier, Bio-One) and each well is
then sonicated for 5 s at 25 % amplitude before being cen-
trifuged at 3000 rpm for 15 min. 20 μl of supernatant is
then loaded into 384 well plates and the fluorescence mea-
sured using the OMEGAstar plate reader system for emis-
sion in the DsRed wavelength (BMG Labtech).
In cell and Pherastar imaging
For automated imaging the InCell Analyzer 2000 (GE
Healthcare) was used to image embryos before using the
Fig. 1 Flow chart of the screening outcomes. The ZF assay can be used to identify neuroprotective compounds that act at different points in the
cascade of mutant sod1 mediated toxicity. Inhibitors would potentially impact the earliest event in sod1 toxicity by reducing the toxic effects of
mutant sod1. Activators may potentially further activate the neuroprotective stress response thus ameliorating the effects of sod1 toxicity
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zebrafish segmentation plugin (GE Healthcare) which al-
lows the user to analyse the fluorescence in individual
tissues. The software segments the zebrafish based upon
the body shape into individual areas such as eye, brain,
liver and spinal cord. Unfortunately, the software cur-
rently only segments the zebrafish accurately at 4dpf and
this limitation introduced variability, making the use of
this software unsuitable for the assay. Fluorescence well
scanning was performed using the Pherastar FS system
(BMG Labtech, 15x15 well scan). This method allows
the user to keep the zebrafish alive after the assay. Un-
fortunately, the well scanning assay is slow for large as-
says (3–4 h per 96 well plate) and thus drastically
reduced the maximum throughput of the assay.
Data analysis and quality control for ZNStress assay
Strictly Standardised Median Difference (SSMD) was
used as the criterion for hit selection in the ZNStress
assay [28]. In HTS screening an important quality con-
trol is to look at how much the positive controls, nega-
tive controls and tested compounds differ from one
another. Readouts such as the Z-Score, signal to noise
(S/N) and signal to background (S/B) are commonly
used in HTS as readouts. These readouts work by com-
paring the values of two different well types in an assay.
S/N and S/B only take the variability of one group into
account and cannot provide quality control data on an
assay with multiple groups. The Z-score takes into ac-
count the variability of two groups being analysed but
not of the whole plate and so does not control the false
positive/negative rate accurately. In addition, these ana-
lysis methods do not take into account the strength of
difference between a test compound and a negative ref-
erence directly, but as a mean value, meaning that
weaker hits can be missed. The SSMD calculates the
median of differences divided by the standard deviation
of the differences between a test compound and a nega-
tive reference [29] and therefore represents the average
fold change penalised by the variability of the fold
change across the plate. SSMD is a more suitable
screen readout for in vivo HTS screening as it takes
into account the variability across the whole plate, giv-
ing each well a readout shown as the magnitude of the
difference in fluorescence compared to the whole plate,
resulting in a more meaningful biological association.
For this assay a threshold of B value < -0.5 or >0.5 was
taken as the cut-off value to identify hit compounds for
further investigation (Additional file 2: Table S1).
Results
Feasibility of Pherastar assay for high throughput
fluorescence quantitation
Pherastar is a fluorescence plate reader that can measure
fluorescence in a matrix format. This allows quantitation
of fluorescence within each well, with high resolution at
hundreds of points. We established that, as opposed to
an image based quantification system (InCell), a direct
high resolution fluorescence detector would be better
for quantitating the DsRed fluorescence while still main-
taining a degree of anatomical specificity. The Pherastar
readout in Additional file 3: Figure S2 demonstrates the
reduction in DsRed signalling following exposure to rilu-
zole. The top rows show riluzole treated zebrafish, while
the bottom row shows the control zebrafish exposed to
DMSO. The data show a large decrease in hsp70-DsRed
activation in the riluzole treated zebrafish, particularly in
the head/brain region. However, consistent orientation
of embryos created a problem in obtaining reproducible
results. Also, the system was relatively slow and there-
fore impacted on the screen throughput capabilities.
Hence, although this assay was more sensitive than
InCell imaging, as it provided a signal intensity based
readout, it was not capable of handling large throughput
screening in a reliable fashion.
Use of whole embryonic extract for high throughput
fluorescence quantitation
While InCell imaging and the Pherastar system provide
an excellent way to measure neuronal stress levels, both
of these systems require careful positioning of embryos,
sophisticated image analysis software and computation
time to analyse the results. We observed that riluzole re-
duced cellular stress in the CNS, and that the CNS was
the primary source of DsRed fluorescence. We decided
to determine if whole embryo extracts would be suffi-
cient to measure the change in fluorescence levels. Such
an assay, if shown to be robust would be beneficial as a
high throughput readout, with enhanced reproducibility
and reduced variability. Towards this we homogenised
the zebrafish larvae by sonication and measured the
fluorescence of the lysate, to determine whether robust
inhibition of DsRed fluorescence was observed in the
presence of the positive control compound, riluzole.
Treatment of embryos from 2dpf to 6dpf with 10 μM
riluzole reduced the DsRed fluorescence by approxi-
mately 50 % (Fig. 2a).
One important aspect of a screen is the success of
identified hit compounds to show a concentration
dependent response in the subsequent validation stage.
To determine if the embryo extracts could be utilized to
measure a dose response to riluzole, embryos were ex-
posed to increasing doses of riluzole and the fluores-
cence measured. Fluorescence quantitation showed a
clear dose-dependent reduction in fluorescence (Fig. 2b),
thus confirming the usefulness of this assay in providing
a good quantitative method for high throughput screen-
ing and drug effect.
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Reduced between and within plate variability when
assessing positive and negative controls using
embryonic extract
As the first step prior to increasing throughput, we de-
termined the assay-to-assay variability. The only source
of variation observed is the day to day variation, due to
the differences in the animals used. To reduce this we
measured the variability observed with the positive and
negative control compounds, between and within
plates (Additional file 4: Figure S3). This variability was
found to be minimal, suggesting that biological vari-
ation between animals should not greatly impact upon
the success of the assay. The quality control analysis of
the control compounds within the plate highlighted the
applicability of this model to identify compounds such
as riluzole that reduce the fluorescence readout of
neuronal stress.
Development and optimisation of the high-throughput
screen
Optimisation of a high-throughput screen was focused
on increasing the number of compounds screened per
week without compromising the sensitivity or specificity
of the assay. Multiple screen lengths were investigated.
The screen was begun at 2dpf as this allows genotyping
before the assay begins, reducing the number of com-
pounds per zebrafish, as well as allowing the zebrafish to
have a further developed nervous system, compared to
24hpf. Shorter assays of 2 and 3 days of drug exposure
showed drug effect, but the reduction in fluorescence
was smaller, which reduces the effect window available
for hit detection. This led to an increased incidence of
false positives and negatives in quality control (QC)
experiments. Drug exposure for 4 days gave a large win-
dow of drug effect, so that compounds only having a
subtle effect were still detectable, which was not be pos-
sible with the shorter drug exposure times.
Multiple endpoint readouts were investigated to iden-
tify the readout that reproducibly gave the most accurate
results while maintaining a high-throughput. Implemen-
tation of robotics systems such as the Echo 550 liquid
handling system (Labcyte) and the InCell 2000 (GE
healthcare) Analyzer further improved the accuracy and
throughput of the screen by automating the genotyping
and dosing steps. The schematic of the final optimised
screening process is shown in Fig. 3.
The high-throughput screen
Development of HT assay QC: use of strictly standardized
median difference with no replicates (SSMD*) in
identification of hits
SSMD* is a method described by Zhang et al in an RNAi
screen. Screens that have a single well, with no repli-
cates, require a method to identify hits within a plate. In
SSMD* analysis, it is assumed that majority of the com-
pounds in the specific plate tested have no efficacy and
thus can be potentially considered as negative controls.
A hit in the plate will stand out as an outlier and thus
can be identified. Hence the median is used to measure
the predominantly inert effects of most compounds in
the assay. The advantage of this approach is that the
whole plate is treated similarly, and hence only wells that
are significantly different from the majority of the wells
with no effects are identified. Using this method we
tested 48 compounds with 12 positive and 12 negative
controls in each plate. The layout of the plate is shown
in Additional file 5: Figure S4. Thus, if most of the com-
pounds in the plate have no effect at all, only the wells
with riluzole should show up as positive hits in the plate.
Figure 4a shows the SSMD scores of a representative
plate in the screen. As expected, only the wells with
Fig. 2 Treatment with riluzole leads to significant quantifiable reduction in neuronal stress. a Zebrafish treated with riluzole show a large reduction in
DsRed fluorescence after treatment with riluzole at 10 μM. N = 19 fish per condition, error bars show SD. P <0.0001. b Dose response analysis was
performed in 96 well plates with 1 embryo/well immersed in varying doses of riluzole (0-30 μM). N = 12 fish per concentration. Error bars show SD
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riluzole showed an SSMD* score of < -0.5 or more. This
step confirmed that legitimate hits can be identified
using this methodology.
QC analysis of positive and negative controls within plates
and between plates
Using the SSMD* analysis we tested the reproducibility
of the assay using riluzole and DMSO controls in each
plate in the screen. The screen included 40 plates with
12 positive and 12 negative controls and 48 test com-
pounds in each plate. The whole screen was then re-
peated a second time. The replicate QC of the screen
using positive and negative controls with SSMD* ana-
lysis set at a < -0.5 cut-off as hits. The sensitivity of the
assay was measured using the formula (#true positive/
(#true positive + #false negative))*100. The specificity of
the assay was measured using the formula (#true nega-
tive/ (#true negative + #false positive))*100. The assay
sensitivity ranged from 94.8–96.8 % and the specificity
from 85.2–93.2 % (Table 1). When the SSMD* cut-off
for hits was reduced to < -1.0, the sensitivity ranged from
79–81 %, while specificity increased to 96.5–98 %
(Table 1).
Hit analysis
Using the cut-off values of < -0.5, <-1.0 (Inhibitors) or >1.0
(Activators) the hits were identified. Figure 4b shows
the SSMD* values of all drugs tested in the screen along
with positive and negative controls on either side. In all
plates screened, riluzole always showed activity. 38
inhibitors of neuronal stress were identified below–0.5
and only 7 below–1.0, which represented 1.9 and
0.35 % of the compounds tested (Table 2). Activators
with SSMD* scores above 1.0 were 20 (1 %) and 142 or
7.1 % of the compounds were toxic, causing death of
the embryos (Table 2). all toxic compounds were
rescreened again at 1 and 0.1 μM concentrations to
detect if any had activity at lower concentrations. How-
ever, none of the toxic compounds showed any stress
modulating activity at lower concentrations. The hits
observed in the screen are realistic, with a small frac-
tion of the total pool showing biological activity and
Fig. 3 Screening flowchart showing the systems used to generate the high-throughput screen
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with the positive and negative controls showing clear
and reproducible effects. The hit compounds were di-
verse comprising of ion channel regulators, steroids,
anti-bacterial, anti-oxidants and anti-inflammatory
compounds, although only one compound showed effi-
cacy to similar levels as riluzole.
Efficacy of compounds previously tested in the sod1
mouse model and/or in ALS clinical trials
Many drug trials have been performed in the SOD1
mouse model and multiple compounds have shown effi-
cacy [1]. However, many of these compounds when
taken to human clinical trials failed to show efficacy.
Additionally, several recent publications have cast doubt
on the efficacy of compounds previously tested [30–34].
Many of the factors affecting the reproducibility of pre-
clinical testing in the SOD1 mouse model have been
standardised and new guidelines have been formulated
[32]. In order to examine whether the positive drug ef-
fects previously identified in the SOD1 mouse model
were reproducible in the mutant Sod1 zebrafish model
of neuronal stress, we evaluated 17 drugs which included
riluzole. Out of all of these compounds only riluzole
Fig. 4 Representative SSMD* scores of a plate and screen replicate from the ZNStress assay. a The plate comprising 12 positive controls (riluzole,
black dots) and 12 negative control (DMSO, black triangles) and 48 test compounds (grey squares) were calculated for SSMD*. Riluzole shows a
clear inhibitory effect and consistently shows a negative SSMD*, while most test compounds and DMSO controls show very little inhibitory
activity. b 2000 compounds from the MicroSource Spectrum library were tested over 40 plates. Positive control for inhibitor of neuronal stress
(riluzole, grey triangle) and negative DMSO controls (black circle) and test compounds (grey circles). A small fraction of drugs in the screen
show biological effects comparable to riluzole and a small fraction of compounds in the library also showed positive SSMD values above 2,
indicating that they were activators. Compounds that showed similar efficacy in two trials were classified as hits
Table 1 Specificity and sensitivity of the screening assay based
upon an SSMD threshold of < -0.5
Replicate 1 Replicate 2
Sensitivity in percentage 94.8 % ± 9.85 96.6 % ± 8.8
Specificity in percentage 85.2 % ± 13.2 93.2 % ± 9.0
The assay statistics from 40 plates in each replicate including 12 positive
control (riluzole) and 12 negative control wells. The false positive and false
negative numbers were utilized to calculate the specificity and sensitivity of
the assay expressed as percentage mean and standard deviation
Table 2 Statistics of assay hits from both replicates of the
high-throughput screen
SSMD Threshold Number of
replicated hits
Number screened Percentage hits
Below -0.5 38 2000 1.9 %
Below -1.0 7 2000 0.35 %
Above 1.0 20 2000 1 %
Caused Death 142 2000 7.1 %
Compounds that showed similar activity in both trials were identified as hits
using the SSMD* threshold criteria as above. SSMD* below -0.5 are inhibitors
of neuronal stress and those above 1.0 are activators of the neuronal heat-shock
stress response
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showed efficacy in reducing neuronal stress (Fig. 5 and
Additional file 6: Table S2). These results are in agree-
ment with previously published reports of the lack of
efficacy of many of these compounds when tested in
follow up pre-clinical studies and/or clinical trials.
Dexpramipexole fails to reduce neuronal stress in the
mutant sod1 zebrafish model of ALS
One of the major clinical trials in ALS to fail at phase 3
after promising phase 2 results, was the recent trial of
dexpramipexole. Interestingly, prior to the human trial,
no pre-clinical mouse data were published. When we
tested dexpramipexole using the mutant Sod1 zebrafish
model, we observed in the first evaluation a statistically
significant effect in the reduction of neuronal stress
(Fig. 6a). However, two follow up studies using the same
preparation and the same batch of the drug failed to
show any reduction in the neuronal stress (Fig. 6b, c).
Overall analysis of the pooled data from triplicate exper-
iments showed that dexpramipexole lacked efficacy in
reducing neuronal stress in this Zebrafish model system.
Discussion
The ZNStress assay is a step forward in pre-clinical
screening for compounds which may exert neuroprotec-
tive effects in ALS, as it links the key characteristics of a
transgenic zebrafish line with screening techniques, to
deliver a truly high-throughput in vivo drug screen. The
only true limiting factor relating to this screen is the
number of embryos available each day and the manual
pipetting of the zebrafish between plates. In its current
format and being run by a single individual, it was com-
fortably possible to screen 4x96 well plates per day twice
per week. This means that a screen of the full library
comprising 2000 compounds in duplicate takes 6 weeks
to complete. This highlights how suitable zebrafish are
for screening and how we are moving towards the abil-
ity to screen hundreds of thousands of compounds in
vivo to identify potential disease modifiers for human
diseases.
Although the primary goal of the reported screen was
to identify compounds that reduce neuronal toxicity
mediated by mutant Sod1, we were also able to use the
same assay to identify compounds that can activate the
cellular stress response mediated by up-regulation of
the heat-shock protein response, which represents a
neuroprotective mechanism [35, 36] (Fig. 1). These
compounds act downstream of the initial insult, i.e. the
activation of the stress response mediated by mutant
Sod1 misfolding and/or its associated toxicity. These
compounds are of interest to the ALS field as activation
of heat shock proteins has been shown to be neuropro-
tective and heat shock protein activators, such as ari-
moclomol, are currently in clinical trials for ALS [35].
Care must be taken as compounds that auto-fluorescence
or are toxic also cause an increase in DsRed fluorescence.
The compounds that activate the stress response can be
further evaluated in secondary screens of efficacy to
separate off-target effects from real heat shock protein
activation.
The question still remains as to how closely a zebrafish
model can mimic a human neurodegenerative disease,
especially as this animal model retains the capacity for
neuroregeneration. Additionally sod1 mutation is a small
sub group comprising of 20 % of familial ALS patients
and may not represent the predominant sporadic form
of ALS. However, some recent data suggesting wildtype
sod1 may be modified to toxic species in a prion like
fashion in sporadic ALS [37], warrants the continued
utility of sod1 based disease models in ALS research.
Nevertheless the wide array of mutations contributing to
ALS pathogenesis require additional genetic models to
cover a broad spectrum of ALS pathogenesis and war-
rant the development of a wider net of screening tools.
The assay described here is an embryonic/larval screen
and hence limits its use to identifying factors involved in
early pathogenesis. It is becoming increasingly evident
that changes in ALS occur far earlier than clinical mani-
festation of the disease occur. This poses a challenge in
treating the disease. It is also becoming increasingly
recognised that potentially clinical stage of disease is too
late for therapeutic intervention [19]. Hence, phenotypic
identification and early diagnosis are gaining importance
Fig. 5 ALS drugs identified in mouse models but lacked clinical efficacy
failed to show efficacy in the ZNStress assay. Percentage reduction
in DsRed fluorescence of 17 drugs that were tested in the mouse
models of ALS from the Microsource Spectrum library. Mean ± SEM
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in therapeutic development for ALS. There is a more
focussed push towards biomarker discovery and ther-
apy development bringing in an era of personalized
medicine [38].
The utility of the ZNStress zebrafish model is shown
by the efficacy of riluzole, the only approved drug used
in the treatment of ALS. Riluzole shows robust inhib-
ition of neuronal stress, demonstrates that drugs which
are active in human ALS also show similar activity in a
zebrafish model. Interestingly, many of the compounds
emerging from murine preclinical studies that failed to
show efficacy in human ALS clinical trials, also showed
no efficacy in the ZNStress assay (Additional file 5: Table
S2). The failure to reproduce positive effects of drugs in
the SOD1 mouse model was ascribed to poor quality
control in pre-clinical studies, necessitating the develop-
ment of international guidelines for drug studies in ro-
dent ALS models [39]. Low animal numbers, lack of
litter matching, transgene copy number variability and
lack of clear endpoints contribute to such spurious ef-
fects [39]. The need for a high degree of rigour in any
pre-clinical evaluation of efficacy is clearly demonstrated
by our experience with dexpramipexole. While one trial
with dexpramipexole showed efficacy (Fig. 6a), follow up
studies showed no efficacy (Fig. 6b, c). Like all HT
screens unknown factors can occasionally lead to a
spurious false positive result and hence the hits need to
be robustly validated subsequently. Thus, high numbers
and multiple screening repeats are key in eliminating
false positive results. An important advantage of zebra-
fish is that we can conduct multiple efficacy studies
using hundreds of embryos from multiple clutches, thus
greatly enhancing the confidence of drug efficacy before
testing in rodent models. We believe that zebrafish
models are unlikely to replace mouse screens, but they
have the ability to identify lead compounds of interest
with high confidence to predict biological activity in a
vertebrate system, thus reducing the number of mouse
studies required. This approach would be expected to
accelerate and reduce the costs of pre-clinical drug
discovery.
Future improvement of the screen described here will
be to adapt the ZNStress assay readout so that the zeb-
rafish can be kept alive after exposure, allowing genetic
modifier and behavioural screens to be performed. An
optimal system for this will be the InCell analyser zebra-
fish plugin as the system can rapidly capture images
(96well plate in 2 wavelengths in 10 min at 2x). This will
allow a decisive readout on which specific tissues and
cell types, show an increase or decrease in fluorescence,
alongside the ability to keep the zebrafish alive for
downstream evaluation. A further potential improve-
ment to the screen will be the implementation of an au-
tomated zebrafish handling system that can selectively
genotype and load zebrafish embryos accurately and rap-
idly into wells, thereby increasing the screen throughput.
Unfortunately, these systems are prohibitively expensive
currently as they are still in development, but in the
future it is likely that these systems will be common
place in zebrafish facilities and will further improve the
screening throughput.
The ZNStress assay is not limited to this particular
zebrafish line, the ALS disease state or the specific field
of biology upon which we have focussed in this report.
The assay can be used in any fluorescence based zebra-
fish screen, as it is flexible and can be applied to mul-
tiple tissue types. We have developed and utilized the
ZNStress assay with transgenic zebrafish carrying
hsp70-DsRed in the context of wildtype sod1 to identify
neurotoxic genes involved in Parkinson’s disease (unpub-
lished data). In the Parkinson’s disease model, the neur-
onal stress produced by specific parkinson mutations
Fig. 6 Experimental variability and occurrence of random efficacy readout in drug trials: Dexpramipexole study. In replicate 1 both riluzole and
dexpramipexole (both 10 μM) showed a significant reduction in DsRed fluorescence. However in replicate 2 and 3 only riluzole showed a
significant reduction in fluorescence. This highlights the need for stringent assay QC and experimental replicates. N= >10 for each replicate, error
bars show SD
McGown et al. Molecular Neurodegeneration  (2016) 11:56 Page 9 of 11
activate the DsRed reporter in the WT-sod1 transgenic
line. The assay process described here utilized imaging
systems that can detect fluorescence at any developmental
stage. The assay can be shortened or extended for differ-
ent lengths of drug exposure and has a readout that can
be performed at different wavelengths. In future, the
development of additional zebrafish models carrying
different ALS mutations is necessary for comprehensive
therapeutic screening and enable personalized medicine.
Conclusions
We conclude that HT drug screening using a mutant
sod1 zebrafish is a reliable model system which supple-
mented with secondary assays would be useful in identi-
fying drugs with potential for neuroprotective efficacy in
ALS.
Additional files
Additional file 1: Figure S1. Embryonic quality control. Bright field
images from Incell Analyzer 2000 of a representative 2 dpf-pre treatment
embryo (Top) and 6 dpf embryos treated with DMSO (Middle) and
Riluzole (Bottom). The embryos appear normal and undergo normal
development. All embryos utilized in the screen were imaged and
quality controlled. (TIF 171 kb)
Additional file 2: Table S1. Table of SSMD β-value hit selection criteria.
(DOC 32 kb)
Additional file 3: Figure S2. Pherastar readout showing the ability to
detect different drug effects in the screen. G93Ros10xAb zebrafish dosed
with riluzole at 10 μM and DMSO. Zebrafish were scanned in a 30x30
point well scan for DsRed fluorescence. The readout is a spectral
representation of DsRed expression from purple/blue = low signal to
yellow/red = high signal. (TIF 1147 kb)
Additional file 4: Figure S3. Variability in percent inhibition within
and between plates in riluzole and DMSO treated wells. A clear separation
of effects of riluzole (black) as compared to the DMSO controls (grey) which
is close to zero change. The well to well variability and between plate
variability as measured by SEM (error bars) shows that variability does
not impact the identification of drug effects compared to DMSO
controls. (TIF 21 kb)
Additional file 5: Figure S4. Plate layout for ZNStress assay. B – Blank,
R - Positive control (riluzole), C- Negative control (DMSO), T- Test
compound. (TIF 307 kb)
Additional file 6: Table S2. Effects of drugs tested in human ALS in
the mutant sod1 ZNSstress assay. (DOC 43 kb)
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